IPO Expected Timetable#

Stock Code	Stock Name	Closing Date*	Allotment Date	Listing Date
09983	CC NEW LIFE	2020/05/07	2020/05/14	2020/05/15
09996	PEIJIA-B	2020/05/07	2020/05/14	2020/05/15

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit <u>www.cfsg.com.hk</u> or contact our account executives or customer service officers

* Applicants please deposit the full amount / margin into the bank account of Celestial Securities Limited no later than 12:00 p.m. in case of cash payment or 4:00 p.m. in case of cheque payment on the Closing Date. If your margin financing is approved and your application for Public Offer Shares is successful (in whole or in part), please deposit the remaining amount of margin no later than 4:00 p.m. on the allotment date.

Central China New Life Limited (9983.HK)

Share Offer Highlights	
Total number of Offer Shares:	300,000,000 Shares (subject to the Over-allotment Option)
- Number of Public Offer Shares:	30,000,000 Shares (subject to reallocation)
- Number of Placing Shares:	270,000,000 Shares (subject to reallocation and the Over-allotment Option)
Number of Shares per Lot:	1,000 Shares
Offer Price:	HKD 5.60 – 7.20 per Share
2019 Historical P/E ratio:	26.14x – 33.61x
Sponsor:	BNP Paribas
Company Quartieur	

Company Overview

The Company is the largest property management service provider in central China region by total GFA under management as of Dec. 31, 2018 and total revenue for the year ended Dec. 31, 2018, according to CIA. As of Dec. 31, 2019, its property management and value-added services covered all 18 prefecture-level cities (and also 81 of the 104 county-level cities) in Henan as well as one city in Hainan, namely Haikou. The Company manages a diversified portfolio of properties, including residential properties, shopping malls, cultural tourism complexes, commercial apartments, office buildings, schools and properties of governmental agencies. It ranked 16th, 15th and 13th among the Top 100 Property Management Companies in China in 2017, 2018 and 2019, respectively, according to CIA.

For the year ended December 31, 2017 and 2018 and 2019, the Company's net profits were RMB23.41 mn, RMB19.47 mn and RMB233.95 mn respectively.

Peijia Medical Limited (9996.HK)

Share Offer Highlights				
Total number of Offer Shares:	152,511,000 Shares (subject to the Over-allotment Option)			
- Number of Public Offer Shares:	15,252,000 Shares (subject to reallocation)			
- Number of Placing Shares:	137,259,000 Shares (subject to reallocation and the Over-allotment Option)			
Number of Shares per Lot:	1,000 Shares			
Offer Price:	HKD 15.36 per Share			
2019 Historical P/E ratio:	-			
Sponsor:	Morgan Stanley, Huatai International			
Company Overview				

Company Overview

The Company focuses on the high-growth interventional procedural medical device market in China, and is a leading domestic player in each of the transcatheter valve therapeutic medical device market and the neurointerventional procedural medical device market in China. It is one of the only four domestic players in the China market with transcatheter aortic valve replacement ("TAVR") products at the clinical trial or more advanced stage, and ranked third in the China transcatheter valve medical device market in terms of the combined number of commercialized products and product candidates in the clinical trial stage, according to Frost & Sullivan. In the meantime, it ranked first among domestic players in the China market in terms of the combined products and product candidates in the clinical trial stage, and was the first domestic player to commercialize an embolization coil product in China, according to Frost & Sullivan.

For the year ended December 31, 2018 and 2019, the Company's net losses were RMB82.63 mn and RMB531.98 mn respectively.



Source		
IPO Prospectus		
Contact Us		
Headquarters:	22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong	(852) 2287 8788
HK Services Centre:	6/F, May May Building,683-685 Nathan Road, Mongkok, Kowloon	(852) 2748 0110
China Services Centre:	1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen 2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai	(86-755) 2216 5888 (86-21) 3227 9888
	6/F, Bank of Guangzhou Square, No. 30 East Zhujiang Road, TianHe District, Guangzhou	(020) 2812 0469
	Rm 2511, TBA Tower, 11 Dongguan Avenue, City East District, Dongguan	(86-769) 2223 0026

Declaration:

The above information is provided and distributed by CASH Financial Services Group Limited ("CASH"). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.